In contrast, KIT alterations in gastrointestinal stromal tumors are more homogeneous, with 70%–90% being exon 11 deletions, and potentially relatedly, KIT inhibitors are an effective standard of care across most patients with KIT-mutated gastrointestinal stromal tumors. Here, KIT is linked to gastrointestinal stromal tumor.